Gut Bacteria Changes Drive Cognitive Decline in Prostate Cancer Patients on ADT
New research reveals how androgen deprivation therapy disrupts gut microbiome and bile acids, causing memory problems through brain signaling pathways.
Summary
Researchers discovered that androgen deprivation therapy (ADT) for prostate cancer causes cognitive impairment through gut microbiome disruption. The treatment depletes beneficial bacteria that produce bile acids, particularly taurodeoxycholic acid (TDCA). This reduction impairs brain signaling pathways in the hippocampus, leading to memory and learning problems. When researchers supplemented mice with TDCA, cognitive function improved, suggesting a potential therapeutic target for the thousands of prostate cancer patients experiencing ADT-related brain fog.
Detailed Summary
Androgen deprivation therapy (ADT) is a cornerstone treatment for advanced prostate cancer, but it comes with a troubling side effect: cognitive impairment that affects memory, executive function, and spatial processing. This "chemo brain"-like phenomenon has puzzled researchers, but new findings reveal the gut microbiome plays a crucial role.
Researchers used a mouse model of prostate cancer to investigate how ADT affects cognition. They discovered that not all mice responded the same way—some developed severe cognitive problems (ADT-susceptible) while others remained largely unaffected (ADT-unsusceptible). The key difference lay in their gut bacteria.
ADT-susceptible mice showed dramatic changes in their microbiome, with significant depletion of bile acid-transforming bacteria including Bacteroides species and Clostridium scindens. This bacterial loss led to reduced production of taurodeoxycholic acid (TDCA), a bile acid that crosses the blood-brain barrier and activates important signaling pathways in the hippocampus—the brain's memory center.
The researchers proved causation through fecal transplant experiments: transferring gut bacteria from cognitively impaired mice to germ-free mice successfully transferred the cognitive deficits. Most importantly, supplementing ADT-susceptible mice with TDCA restored cognitive function by reactivating the TGR5-ERK1/2 signaling pathway in the hippocampus.
These findings offer hope for the estimated 500,000+ men in the US receiving ADT. Rather than accepting cognitive decline as an inevitable side effect, targeted interventions to restore beneficial gut bacteria or supplement specific bile acids could preserve brain function during cancer treatment.
Key Findings
- ADT depletes bile acid-producing gut bacteria, particularly Bacteroides and Clostridium scindens
- Reduced taurodeoxycholic acid (TDCA) impairs hippocampal TGR5-ERK1/2 brain signaling
- Fecal transplants from cognitively impaired mice transfer cognitive deficits to healthy mice
- TDCA supplementation restores cognitive function in ADT-treated mice
- Only subset of ADT patients may be susceptible to microbiome-mediated cognitive decline
Methodology
Researchers used PC3 prostate cancer cell-bearing mice with surgical castration to model ADT. Cognitive function was assessed through behavioral tests (Y-maze, novel object recognition). Gut microbiome was analyzed via 16S rRNA sequencing, and bile acid profiles measured using targeted metabolomics.
Study Limitations
Study conducted in mouse models may not fully translate to humans. The specific bacterial strains and bile acid concentrations needed for therapeutic intervention in patients remain to be determined. Long-term safety of bile acid supplementation requires investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.